RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
The use and misuse of vancomycin in very low birth weight infants
Knorr, K., Hetherington, S., & Saker, F. (2008). The use and misuse of vancomycin in very low birth weight infants. Journal of Neonatal-Perinatal Medicine, 1(4), 217-220.
Objective: To evaluate vancomycin use during late-onset sepsis evaluation in very low birth weight infants (VLBW). Study design: Data on late-onset sepsis and antibiotic use, including vancomycin containing regimens, were analyzed and reported from 53 neonatal intensive care units participating in a randomized placebo-controlled trial of Veronate® for VLBW infants. Results: Of 505 infants enrolled in the study, 387 (77%) had at least one evaluation for late-onset sepsis. Of these infants, 108 (28%) had one or more positive blood cultures. Two hundred thirty-three (60%) infants evaluated for late-onset sepsis received empiric vancomycin. Twenty-one of 33 neonatal intensive care units included vancomycin as empiric therapy more than 50% of the time. Conclusions: Vancomycin exposure rates for first evaluations of late-onset sepsis are high. Strategies to optimize antibiotic use should minimize consequences of late-onset sepsis while limiting antibiotic pressure for development of resistance.